EPOCH

Clinical Trial Information

Protocol TS-102 / NCT01483027


An open-label, prospective, multicenter, randomized, Phase III clinical trial evaluating yttrium-90 transarterial radioembolisation with TheraSphere in patients with metastatic colorectal carcinoma (mCRC) of the liver who have failed first-line chemotherapy.25,26


RANDOMIZE TREATMENT GROUP

TheraSphere plus standard-of-care chemotherapy: oxaliplatin- or irinotecan-based


CONTROL GROUP

Standard-of-care chemotherapy: oxaliplatin- or irinotecan-based


OBJECTIVE

To evaluate the efficacy and safety of TheraSpherein patients with mCRC of the liver scheduled to receive second-line chemotherapy.


ENDPOINTS

Primary: Progression-free survival (per RECIST v1.1)
Secondary: Safety, Overall survival, tumour response, time to symptomatic progression, hepatic progression-free survival, quality of life
(FACT-C)

 

Please visit the  THERASPHERE TRIALS WEBSITE for more details